These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33361304)

  • 21. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers.
    Hodges MR; Ople E; Wedel P; Shaw KJ; Jakate A; Kramer WG; Marle SV; van Hoogdalem EJ; Tawadrous M
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0162322. PubMed ID: 36988461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.
    Warn PA; Livermore J; Howard S; Felton TW; Sharp A; Gregson L; Goodwin J; Petraitiene R; Petraitis V; Cohen-Wolkowiez M; Walsh TJ; Benjamin DK; Hope WW
    Antimicrob Agents Chemother; 2012 Feb; 56(2):708-14. PubMed ID: 22123680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.
    Louie A; Liu W; Miller DA; Sucke AC; Liu QF; Drusano GL; Mayers M; Miller MH
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2831-40. PubMed ID: 10582868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fosmanogepix: The Novel Anti-Fungal Agent's Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials.
    Almajid A; Bazroon A; Al-Awami HM; Albarbari H; Alqahtani I; Almutairi R; Alsuwayj A; Alahmadi F; Aljawad J; Alnimer R; Asiri N; Alajlani S; Alshelali R; Aljishi Y
    Cureus; 2024 Apr; 16(4):e59210. PubMed ID: 38807795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis.
    Giamberardino CD; Schell WA; Tenor JL; Toffaletti DL; Palmucci JR; Marius C; Boua JK; Soltow Q; Mansbach R; Moseley MA; Thompson JW; Dubois LG; Hope W; Perfect JR; Shaw KJ
    mBio; 2022 Dec; 13(6):e0234722. PubMed ID: 36222509
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Jørgensen KM; Astvad KMT; Arendrup MC
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513793
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Zhu Y; Kilburn S; Kapoor M; Chaturvedi S; Shaw KJ; Chaturvedi V
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis.
    Gebremariam T; Alkhazraji S; Alqarihi A; Jeon HH; Gu Y; Kapoor M; Shaw KJ; Ibrahim AS
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.
    Hope WW; Mickiene D; Petraitis V; Petraitiene R; Kelaher AM; Hughes JE; Cotton MP; Bacher J; Keirns JJ; Buell D; Heresi G; Benjamin DK; Groll AH; Drusano GL; Walsh TJ
    J Infect Dis; 2008 Jan; 197(1):163-71. PubMed ID: 18171300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris
    Vazquez JA; Pappas PG; Boffard K; Paruk F; Bien PA; Tawadrous M; Ople E; Wedel P; Oborska I; Hodges MR
    Antimicrob Agents Chemother; 2023 May; 67(5):e0141922. PubMed ID: 37022196
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Shaheen SK; Juvvadi PR; Allen J; Shwab EK; Cole DC; Asfaw YG; Kapoor M; Shaw KJ; Steinbach WJ
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0068221. PubMed ID: 34310205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of antifungal efficacies of moxifloxacin, liposomal amphotericin B, and combination treatment in experimental Candida albicans endophthalmitis in rabbits.
    Deren YT; Ozdek S; Kalkanci A; Akyürek N; Hasanreisoğlu B
    Can J Microbiol; 2010 Jan; 56(1):1-7. PubMed ID: 20130687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia.
    Cornely OA; Ostermann H; Koehler P; Teschner D; Limburg E; Kramer WG; Barbat SH; Tawadrous M; Hodges MR
    J Antimicrob Chemother; 2023 Nov; 78(11):2645-2652. PubMed ID: 37681450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraocular penetration of micafungin in patient with Candida albicans endophthalmitis.
    Mochizuki K; Suemori S; Udo K; Komori S; Ohkusu K; Yamada N; Ogura S
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):531-3. PubMed ID: 21751880
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Shaw KJ; Schell WA; Covel J; Duboc G; Giamberardino C; Kapoor M; Moloney M; Soltow QA; Tenor JL; Toffaletti DL; Trzoss M; Webb P; Perfect JR
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [CARD9 Mutation in a Patient with Candida albicans Meningoencephalitis; A Case Report].
    Kuruoğlu T; Çelik M; Çelmeli F; Tanyel E
    Mikrobiyol Bul; 2021 Oct; 55(4):656-664. PubMed ID: 34666665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitreous and aqueous penetration of intravitreally and orally administered moxifloxacin in an experimental rabbit model of fungal endophthalmitis.
    Arikan S; Ozdek S; Aktas Z; Dinçel A; Hasanreisoglu B
    J Pharm Pharmacol; 2013 May; 65(5):659-64. PubMed ID: 23600382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix.
    August BA; Kale-Pradhan PB
    Pharmacotherapy; 2024 Jun; 44(6):467-479. PubMed ID: 38721866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.
    Hoenigl M; Sprute R; Arastehfar A; Perfect JR; Lass-Flörl C; Bellmann R; Prattes J; Thompson GR; Wiederhold NP; Al Obaidi MM; Willinger B; Arendrup MC; Koehler P; Oliverio M; Egger M; Schwartz IS; Cornely OA; Pappas PG; Krause R
    Expert Opin Investig Drugs; 2022 Aug; 31(8):795-812. PubMed ID: 35657026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial.
    Pappas PG; Vazquez JA; Oren I; Rahav G; Aoun M; Bulpa P; Ben-Ami R; Ferrer R; Mccarty T; Thompson GR; Schlamm H; Bien PA; Barbat SH; Wedel P; Oborska I; Tawadrous M; Hodges MR
    J Antimicrob Chemother; 2023 Oct; 78(10):2471-2480. PubMed ID: 37596890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.